Phaseline

Targets › HTR3A

HTR3A (5-hydroxytryptamine receptor 3A): drug programs, companies and trials

14 programs from 14 companies in 19 trials: 8 Phase 2, 6 Phase 4, 4 Phase 3, 1 Phase 1; Oncology, Other, Genitourinary; next expected readout Dec 2026.

Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons. (UniProt, P46098)

Open in Phaseline: the race on HTR3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai 6th People's HospitalPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 4Chemotherapy-induced Nausea and VomitingDec 2026
Sanliurfa Education and Research Hospitalmetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 4Intraoperative Nausea-retching-vomiting EpisodesJan 2027
Heron TherapeuticsGranisetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 4Chemotherapy-Induced Nausea and Vomiting (CINV); TMD; Nausea With Vomiting Chemotherapy-Induced; Nephrotoxicity–
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 4Endometrial Cancer–
University of Colorado, DenverPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 3NephrotoxicitySep 2027
Affiliated Hospital of Qinghai UniversityMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 3NauseaDec 2027
TakedaVortioxetine
Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist
HTR1A, SLC6A4, HTR3APhase 3Major Depressive Disorder; Glioblastoma; DepressionSep 2029
Seoul National University HospitalRamosetron
Serotonin 3 (5-HT3) receptor antagonist
HTR3A, HTR3E, HTR3B, HTR3D, HTR3CPhase 2Fecal IncontinenceDec 2026
Second Affiliated Hospital, Zhejiang University, School of MedicinePalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 2Esophagus CancerJan 2027
Simon FisherMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 2Hypoglycemia UnawarenessJun 2027
Mahidol Universitypalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 2Cancer (Solid Tumors)Oct 2027
Chinese University of Hong KongPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 2Breast CancerDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 2Solid Tumor CancerJan 2028
Tianjin Medical University Cancer Institute and HospitalPalonosetron
Serotonin 3a (5-HT3a) receptor antagonist
HTR3APhase 2Chemotherapy-Induced Nausea and Vomiting (CINV)Jun 2028

Conditions

Nephrotoxicity (2) Chemotherapy-Induced Nausea and Vomiting (CINV) (2) TMD (1) Nausea With Vomiting Chemotherapy-Induced (1) Solid Tumor Cancer (1) Major Depressive Disorder (1) Glioblastoma (1) Depression (1) Endometrial Cancer (1) Breast Cancer (1) Cancer (Solid Tumors) (1) Chemotherapy-induced Nausea and Vomiting (1)

Modalities

small molecule (13), protein or peptide (1)

Companies

University of Colorado, Denver (1) Tianjin Medical University Cancer Institute and Hospital (1) Heron Therapeutics (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Takeda (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Chinese University of Hong Kong (1) Mahidol University (1) Shanghai 6th People's Hospital (1) Affiliated Hospital of Qinghai University (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Sanliurfa Education and Research Hospital (1) Simon Fisher (1) Seoul National University Hospital (1)

Related targets

DRD2 (3) HTR4 (3) HTR1A (1) SLC6A4 (1) HTR3E (1) HTR3B (1) HTR3D (1) HTR3C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.